| Identification | Back Directory | [Name]
Lacidipine 13C8 | [CAS]
1261432-01-2 | [Synonyms]
Lacidipine 13C8
13C8]-Lacidipine
Lacidipine 13C8Q: What is
Lacidipine 13C8 Q: What is the CAS Number of
Lacidipine 13C8 Q: What is the storage condition of
Lacidipine 13C8 Q: What are the applications of
Lacidipine 13C8 |
| Hazard Information | Back Directory | [Uses]
Lacidipine-13C8 is the deuterium labeled Lacidipine[1]. Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI)[2][3]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Zhang A, et al. Lacidipine attenuates apoptosis via a caspase-3 dependent pathway in human kidney cells. Cell Physiol Biochem. 2013;32(4):1040-9.
[3] Cristofori P, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000 Oct;18(10):1429-36. DOI:10.1097/00004872-200018100-00010 |
|
|